Clinical Trial

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type of HIF-2α inhibitor) * Zimberelimab (a type of monoclonal antibody)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-02.
Status change: Not Yet Recruiting → Recruiting 2026-03-18
Trial Details
NCT Number NCT07397611
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Arcus Biosciences, Inc.
Conditions Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma
Enrollment 32 participants
Start Date 2026-03-09
Primary Completion 2028-01-31 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-20